Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,887,010
  • Shares Outstanding, K 165,830
  • Annual Sales, $ 2,171 M
  • Annual Income, $ 186,000 K
  • 36-Month Beta 0.25
  • Price/Sales 2.16
  • Price/Cash Flow 13.33
  • Price/Book 2.48

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.13 +2.45%
on 05/21/18
32.74 -11.97%
on 04/24/18
-3.24 (-10.11%)
since 04/23/18
3-Month
28.13 +2.45%
on 05/21/18
34.84 -17.28%
on 02/27/18
-4.77 (-14.20%)
since 02/23/18
52-Week
28.13 +2.45%
on 05/21/18
42.97 -32.93%
on 07/19/17
-10.25 (-26.23%)
since 05/23/17

Most Recent Stories

More News
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y

Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.

LGND : 190.74 (+1.95%)
ILMN : 271.73 (+0.34%)
ENTA : 97.62 (-2.88%)
RDY : 28.82 (-2.21%)
Dr. Reddy's to Release Q4 and Full Year FY18 Results on May 22, 2018

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Fourth Quarter and Full year ended March 31, 2018 on Tuesday, May 22, 2018 after the Board Meeting....

RDY : 28.82 (-2.21%)
BioSim Pharmaceuticals Selects CPC Scientific as Key Supplier in the Manufacture of BioSim's ACTH Gel

BioSim Pharmaceuticals, Inc. today announced that it has selected CPC Scientific to supply BioSim with their cGMP ACTH peptide. BioSim's ACTH Gelatin Depot 80 IU/mL product is a copy of the...

RDY : 28.82 (-2.21%)
MNK : 16.33 (+1.37%)
Dr. Reddy's Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and its subsidiary, Promius Pharma, LLC today announced the filing of New Drug Application (NDA) for its migraine candidate...

RDY : 28.82 (-2.21%)
BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod

BioMarin's (BMRN) MAA submission for its pipeline PKU candidate, pegvaliase, gets accepted in the EU. The same is under priority review in the United States with decision awaited this May.

ENDP : 6.38 (+7.23%)
RDY : 28.82 (-2.21%)
BMRN : 88.46 (+0.97%)
REGN : 295.31 (+0.21%)
Dr. Reddy's Laboratories Announces Senior Leadership Changes

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced a change in the makeup of its senior leadership team.

RDY : 28.82 (-2.21%)
Dr. Reddy's Laboratories Announces the Launch of Palonosetron Hydrochloride Injection in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Palonosetron Hydrochloride Injection, 0.25 mg (base)/ 5 mL, a therapeutic equivalent...

RDY : 28.82 (-2.21%)
Blog Exposure - Dr. Reddy's Launches its Levocetirizine Dihydrochloride Tablets in the US Market

Stock Monitor: Amphastar Pharma Post Earnings Reporting

RDY : 28.82 (-2.21%)
AMPH : 16.59 (-0.30%)
Dr. Reddy's Laboratories Announces the Launch of Levocetirizine Dihydrochloride Tablets USP, 5 mg in the U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic...

RDY : 28.82 (-2.21%)
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

BAYRY : 30.2100 (-2.45%)
AZN : 36.84 (-0.57%)
RDY : 28.82 (-2.21%)
ADMS : 29.33 (-1.38%)
TEVA : 21.15 (+0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade RDY with:

Business Summary

Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally,...

See More

Key Turning Points

2nd Resistance Point 29.16
1st Resistance Point 28.99
Last Price 28.82
1st Support Level 28.57
2nd Support Level 28.32

See More

52-Week High 42.97
Fibonacci 61.8% 37.30
Fibonacci 50% 35.55
Fibonacci 38.2% 33.80
Last Price 28.82
52-Week Low 28.13

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar